Dexmedetomidine Sedation and Cardiopulmonary Bypass
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
Dexmedetomidine is a unique sedative anesthetic agent that allows accurate control of the
depth of sedation and provides analgesia, cardio protection, renal protection, and
neuroprotection without causing respiratory depression. It is an alpha 2-adrenoreceptor
agonist that modulates the release of catecholamines from the central and autonomic nervous
systems. When patients sedated by dexmedetomidine are allowed to become responsive, they are
calm and cooperative (1). No other sedative agent has this feature, and sedated patients
frequently awaken in a confused state. Investigators are conducting this study project to
compare between dexmedetomidine based and propofol based anesthetic techniques with regard to
hemodynamic changes, stress hormone release as well as cytokines in patients undergoing CPB
for coronary revascularization.